Back
BioMarin Pharmaceutical Inc. (BMRN)
BiotechnologyBMRN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$54.80
−0.17%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$1.77
ROE
4.5%
Gross margin
51.2%
Debt/Equity
0.23x
Revenue growth
2.8%
BioMarin Pharmaceutical Inc. — company intelligence
Earnings surprises
Q2 2026$0.73 vs $0.70 est+4.0%
Q1 2026$0.54 vs $0.77 est-29.5%
Q4 2025$-0.24 vs $0.64 est-137.7%
Q3 2025$-0.16 vs $0.38 est-142.2%
Analyst consensus · 35 analysts
27 Buy8 Hold0 Sell
Updated Oct 9, 2026
Insider activity · 90 days
1 buy2 sellsnet -15,503 shares
Friberg Gregory RSell 4,086 · Sep 30, 2026
Plenge Robert MBuy 6,140 · Sep 10, 2026
Davis George EricSell 17,557 · Sep 2, 2026
Recent SEC filings
8-K — Material event reportOct 6, 2026
4 — Insider transaction reportOct 1, 2026
8-K — Material event reportSep 30, 2026
Latest news
Tracking John Paulson's Paulson & Company Portfolio: Q2 2026 Update — SeekingAlpha · 2w ago
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? — Yahoo · 3w ago
Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative? — Yahoo · 3w ago
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone — Yahoo · 3w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.